Next Article in Journal
Population Structure and Genetic Diversity of the Fusarium graminearum Species Complex
Next Article in Special Issue
Anthrax Lethal Toxin-Induced Gene Expression Changes in Mouse Lung
Previous Article in Journal
Molecular Analysis of the Interaction of the Snake Venom Rhodocytin with the Platelet Receptor CLEC-2
Previous Article in Special Issue
Mechanism of Lethal Toxin Neutralization by a Human Monoclonal Antibody Specific for the PA20 Region of Bacillus anthracis Protective Antigen
Toxins 2011, 3(8), 1004-1019; doi:10.3390/toxins3081004
Review

Monoclonal Antibody Therapies against Anthrax

1,* , 2
 and
1
1 Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA 2 Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
* Author to whom correspondence should be addressed.
Received: 10 June 2011 / Revised: 6 August 2011 / Accepted: 10 August 2011 / Published: 15 August 2011
(This article belongs to the Special Issue Anthrax Toxin)
View Full-Text   |   Download PDF [197 KB, uploaded 15 August 2011]   |  

Abstract

Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.
Keywords: Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule mAbs; post-exposure treatment of anthrax; a cocktail of mAbs Bacillus anthracis; anti-PA mAbs; anti-LF mAbs; anti-EF mAbs; anti-capsule mAbs; post-exposure treatment of anthrax; a cocktail of mAbs
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal Antibody Therapies against Anthrax. Toxins 2011, 3, 1004-1019.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert